What Vela Diagnostics Pte. Ltd. does

Vela Diagnostics Pte. Ltd. is a Singapore-headquartered molecular diagnostics company that designs, manufactures, and sells integrated sample-to-result PCR and next-generation sequencing (NGS) solutions under the Sentosa platform brand. The platform combines nucleic acid extraction and PCR setup (Sentosa SX101), template preparation (Sentosa ST401), sequencing (Sentosa SQ301), and automated data analysis and reporting (Sentosa SQ Reporter and Sentosa SA201 Reporter) into a single workflow, with both IVD/CE-IVD cleared and RUO configurations. Vela's assay menu is organized under four sub-brands: ViroKey for virology (SARS-CoV-2 with FDA EUA, monkeypox, HIV, HCV, HBV, CMV genotyping), PathoKey for microbiology and pathogen detection (UTI ID and AMR panels, comprehensive pathogen identification of over 2,000 targets), OncoKey for oncology NGS panels (NSCLC, leukemia, hereditary cancer, pan-cancer), and ViroKey/PathoKey quantitative transplant monitoring tests (BKV, CMV, EBV, HSV, VZV, HHV6).

The company serves four primary customer segments: clinical and hospital laboratories, oncology testing laboratories, research institutions purchasing RUO products, and pharmaceutical partners for companion diagnostics development. Revenue is generated through a mix of one-time instrument sales (Sentosa SX101, SQ301, ST401, SA201, Rotor-Gene Q MDx, GB Analyzer), recurring consumables and reagents (extraction kits, library prep kits, sequencing kits, template kits, chip kits), software licenses (Sentosa SQ Reporter, SA201 Reporter), and pharmaceutical partnering arrangements. The Sentosa platform is CE-IVD certified, with select tests holding FDA EUA, Australian TGA, and CLIA high-complexity authorizations, and the products comply with CFR 21 Part 11 for electronic records and signatures. Go-to-market combines regional direct sales (offices in Singapore for APAC/MEA, Hamburg for EMEA, and Fairfield NJ for the Americas) with a global distributor network, including a new exclusive EMEA distribution agreement with ABL Diagnostics (Euronext: ABLD) effective January 2026.

Vela was founded in 2011, operates with 101-250 employees, and is a subsidiary of Vela Diagnostics Holding Pte Ltd, which owns the registered trademarks for Sentosa, OncoKey, PathoKey, and ViroKey across the US, EU, PRC, and UK. The leadership team is led by Sam Dajani (Chairman and CEO), with Dr. Charlie Lee heading research and development and Scott Cassidy overseeing business development. The company acquired Lifecode's Data Interpretation Assets in May 2016 and received a modest Biomedical Advanced Research and Development Authority (BARDA) award of $225,000 in April 2020. There is no public listing and no disclosed venture or growth equity funding in the source material.

Name

Vela Diagnostics Pte. Ltd.

Legal name

Vela Diagnostics Pte. Ltd.

Website

https://veladx.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

Vela Diagnostics is a Singapore-based molecular diagnostics company providing integrated PCR and NGS sample-to-result solutions on the Sentosa platform. It serves hospital and oncology laboratories, research institutions, and pharmaceutical partners across the Americas, EMEA, and Asia Pacific.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Instruments and Assays

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Molecular diagnostics platforms
• Automated PCR workflows
• Next-generation sequencing
• Infectious disease testing
• Clinical laboratory automation

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Instrument Sales: Sale of automated molecular diagnostics instruments including Sentosa SX101, SQ301, ST401, SA201, RGQ, and GB Analyzer. Instruments sold with perpetual licenses.
2. Consumables and Reagents: Recurring sales of PCR and NGS assay kits, extraction kits, library preparation kits, sequencing kits, template kits, and chip kits. Consumables sold in packs of 4-96 tests.
3. Software Licenses: Sale of software solutions including Sentosa SQ Reporter and SA Reporter with server and perpetual license options. Includes both IVD and RUO versions.
4. Pharma Partnering: Collaborative partnerships with pharmaceutical companies for companion diagnostics development and validation.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Vela Diagnostics designs, manufactures, and sells an integrated sample-to-result molecular diagnostics platform (Sentosa) that combines automated nucleic acid extraction, PCR setup, NGS template preparation, sequencing, and data analysis/reporting instruments, software, and validated assay kits for infectious disease, oncology, and antimicrobial resistance testing in clinical and reference laboratories.

Product overview

Vela Diagnostics is a global provider of integrated molecular diagnostics solutions offering standardized, automated PCR and NGS workflow products. The Sentosa platform provides an integrated sample-to-result system combining nucleic acid extraction (Sentosa SX101), PCR setup, template preparation (Sentosa ST401), sequencing (Sentosa SQ301), and automated data analysis/reporting (Sentosa SQ Reporter, Sentosa SA Reporter). The company offers broad PCR assay portfolios under the ViroKey and PathoKey brands covering infectious diseases (respiratory viruses including SARS-CoV-2, Monkeypox, influenza; virology including HIV, HCV, HBV, CMV; antimicrobial resistance), transplant monitoring (BKV, CMV, EBV, HSV, VZV, HHV6), and oncology (NGS-based cancer panels including OncoKey panels for NSCLC, leukemia, and hereditary cancer). The product ecosystem supports both fully automated high-throughput workflows (with <30 minutes hands-on time) and flexible manual options. The Sentosa platform is CE-IVD certified and FDA-cleared, with regulatory approvals across multiple global markets.

Differentiator

Problem solved

Functional benefit

Brands

• Sentosa: Automated platform for NGS and PCR testing workflows including instruments SX101, SQ301, ST401, and SA201
• OncoKey
• PathoKey
• ViroKey

Products and services

• Sentosa SX101

Quantifiable outcome

• Up to 48 samples processed within 2 hours using SX101 automated extraction
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability9 records

Feature7 records

Partnerships

One partnership is on record.

• ABL DiagnosticscoreChannel Partner/ Reseller/ Distributor · 28 July 2025Strategic channel partnership where ABL Diagnostics becomes the exclusive distributor of Vela's CE-IVD automated PCR and NGS platforms across Europe, Middle East, and Africa (EMEA), starting January 2026 following a non-exclusive transition phase in July 2025. The partnership combines Vela's automation and validated assay portfolio with ABL's specialized PCR/NGS kits, DeepChek NGS software, UltraGene real-time PCR kits, and Nadis electronic medical record system deployed in over 200 hospitals in France. ABL brings over two decades of molecular diagnostics experience and distribution in over 40 countries.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Strengths4 records

Weaknesses2 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/veladiagnostics
• YouTubeyoutube.com/channel/UC4Xiyrr_MSzFT2-N_ZtfwKg
• Facebookfacebook.com/VelaDiagnostics
• LinkedInlinkedin.com/company/vela-diagnostics
• Instagraminstagram.com/veladiagnostics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vela Diagnostics Pte. Ltd.